Ftse Mib
33.872,79
0,72%
DAX
18.134,14
0,78%
S&P 500
5.155,05
0,53%
NASDAQ
16.156,33
0,00%
Bitcoin
63.883,39
-0,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Fate Therapeutics Inc (FATE) Fate Therapeutics Inc (FATE) Notizie

Fate Therapeutics Inc

FATE
4,23
0,17 (4,19%)
Pre Mercato
Ultimo aggiornamento: 15:10:28
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/5/202414:00GLOBEFate Therapeutics to Webcast Conference Call Reporting First..
03/5/202422:30GLOBEFate Therapeutics Announces Presentation of FT522..
22/4/202422:30GLOBEFate Therapeutics Announces Presentation of FT819..
03/4/202414:00GLOBEFate Therapeutics to Present at 23rd Annual Needham Virtual..
02/4/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Award..
19/3/202413:44GLOBEFate Therapeutics Announces Pricing of $100 Million..
05/3/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Award..
04/3/202419:29EDGAR2Form 144 - Report of proposed sale of securities
01/3/202414:00GLOBEFate Therapeutics to Present at Upcoming March Investor..
26/2/202422:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
26/2/202422:03EDGAR2Form 8-K - Current report
26/2/202422:01GLOBEFate Therapeutics Reports Fourth Quarter and Full Year 2023..
15/2/202414:00GLOBEFate Therapeutics to Webcast Conference Call Reporting..
13/2/202400:06EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Awards..
30/1/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202419:44EDGAR2Form 144 - Report of proposed sale of securities
25/1/202422:19EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:39EDGAR2Form 144 - Report of proposed sale of securities
09/1/202422:36EDGAR2Form 144 - Report of proposed sale of securities
09/1/202422:36EDGAR2Form 144 - Report of proposed sale of securities
09/1/202422:35EDGAR2Form 144 - Report of proposed sale of securities
08/1/202414:00GLOBEFate Therapeutics Announces Initiation of Phase 1 Clinical..
03/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:17EDGAR2Form 144 - Report of proposed sale of securities
19/12/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202317:40EDGAR2Form 144 - Report of proposed sale of securities
13/12/202323:00GLOBEFate Therapeutics Reports New Employee Inducement Grants..
28/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202317:57EDGAR2Form 144 - Report of proposed sale of securities
08/11/202323:10EDGAR2Form 8-K - Current report
08/11/202322:44EDGAR2Form S-3 - Registration statement under Securities Act of..
08/11/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:03EDGAR2Form 8-K - Current report
08/11/202322:01GLOBEFate Therapeutics Reports Third Quarter 2023 Financial..
25/10/202314:00GLOBEFate Therapeutics to Webcast Conference Call Reporting Third..
01/9/202323:29EDGAR2Form 8-K - Current report
31/8/202314:00GLOBEFate Therapeutics to Present at Upcoming September Investor..
21/8/202322:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202321:58EDGAR2Form 144 - Report of proposed sale of securities
Apertura: Min: Max:
Chiusura: 4,06

La tua Cronologia

NASDAQ
FATE
Fate Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network